Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (29860)	1/3/2000 5:21:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 32384

Torben, For some reason, the number $100,000,000 sticks in my mind as to the breakeven point for LGND ..as for revenues. Therefore, if Panretin and the other drug(can't remember name at moment)can generate $50M and Targretin produce $100M, we are looking at a nice earnings number for LGND. However, it will probably be the third Q before we seen any discernible results IMO.

To: Torben Noerup Nielsen who wrote (29860)	1/3/2000 6:04:00 PM
From: Skeeter Bug	Read Replies (1) \| Respond to of 32384

tnn, profitability depends a lot on future decisions. i'm quite positive that lgnd could spend all the money they earn for many years if they decided to vigorously develop EVERYTHING in their pipeline. a lot depends on management finesse. i'll review th numbers (which i have ignored for some time b/c lgnd was so undervalued - worth the research to develop a new value model) from an "all else being equal" standpoint. but again, IF management wanted to, they could spend more than they could ever make to develop potential products. this is why management is so important and why i hope lgnd management 1. isn't as bad as the street says or 2. they learn from past errors. like it or not, they report to investors. i hope they understand this.